Genomic Dynamics of Carbapenemase-Encoding Genes in Carbapenem-Resistant Enterobacter cloacae: Evidence from Guangdong Province

Study Background and Research Question

Carbapenem-resistant Enterobacter cloacae (CREC) has emerged as a critical public health threat due to its rising prevalence and capacity for multidrug resistance. During the COVID-19 pandemic, increased antibiotic use and healthcare disruptions have further complicated resistance emergence and spread. Yet, detailed studies on the genetic characteristics and transmission patterns of carbapenemase-encoding genes (CEGs) in CREC, especially in high-risk clinical settings, have been scarce. The recent study by Chen et al. (2025) addresses this gap by analyzing genetic and epidemiological features of CREC isolates from eight teaching hospitals in Guangdong, China, collected between December 2022 and June 2024 (paper).

Key Innovation from the Reference Study

The pivotal contribution of this work is the comprehensive mapping of CEG carriage (notably blaNDM−1, blaIMP, and blaKPC−2) in clinical CREC isolates at both plasmid and chromosomal levels. By combining molecular typing, conjugation assays, and mobile genetic element identification, the authors elucidate not just the presence of resistance determinants but also their mechanisms of horizontal and vertical transfer in real-world hospital environments (paper). This integrative approach moves beyond simple gene detection, offering mechanistic insights into the persistence and spread of resistance within and between healthcare institutions.

Methods and Experimental Design Insights

The study analyzed 54 non-duplicate CREC isolates using a combination of:

• Variable temperature SDS plasmid elimination for discerning plasmid-borne CEGs,
• Polymerase Chain Reaction (PCR) to detect specific carbapenemase genes (blaNDM−1, blaIMP, blaKPC−2),
• Broth microdilution for antimicrobial susceptibility profiling,
• ERIC-PCR and NTSYS software for genotyping and phylogenetic clustering,
• Conjugation experiments to assess horizontal gene transfer capacity,
• Mobile genetic element analysis to identify insertion sequences (notably ISEcp1 and others).

Such a multi-pronged design enables robust correlation between genotype, transmission potential, and phenotypic resistance, while allowing epidemiological associations across patient demographics and clinical sources (paper).

Core Findings and Why They Matter

High CEG Prevalence and Diversity: 85.19% (46/54) of CREC isolates harbored at least one CEG (paper). The blaNDM−1 gene was predominant, present on both plasmids and chromosomes in 33.33% (18/54) and exclusively on plasmids in 46.30% (25/54) of isolates. The blaIMP gene was less common, while co-occurrence of blaNDM−1 and blaKPC−2 was rare.

Enhanced Multidrug Resistance: Strains positive for CEGs showed significantly higher resistance rates to imipenem, cefepime, gentamicin, ceftazidime/avibactam, ciprofloxacin, and levofloxacin compared to CEG-negative isolates (P<0.05) (paper). This underscores the clinical implications of CEG carriage for antibiotic stewardship and infection control.

High Horizontal Transferability: Conjugation experiments demonstrated that 95.65% (44/46) of CEGs, including nearly all blaNDM−1 and all blaIMP, were transferable via plasmids, indicating a strong capacity for horizontal gene spread among Enterobacteriaceae (paper).

Mobile Genetic Element Prevalence: Six types of mobile genetic elements were identified, with ISEcp1 being most prevalent (87.04%, 47/54). 40.74% (22/54) of isolates carried four types concurrently, suggesting a rich reservoir for gene mobilization and recombination.

Genotypic Diversity and Epidemiology: ERIC-PCR classified the isolates into 17 genotypes, with types E and G being most common and widely distributed across departments. Higher detection rates were observed in male, elderly patients, respiratory departments, and sputum samples, highlighting epidemiological risk clusters (paper).

Protocol Parameters

• assay | PCR detection of blaNDM−1, blaIMP, blaKPC−2 | n/a | Enables rapid screening of CEGs in Enterobacteriaceae | paper
• assay | Broth microdilution | MIC (varies by drug, e.g., imipenem ≥8 μg/mL) | Standard for antimicrobial susceptibility testing in multidrug resistance studies | paper
• assay | Plasmid conjugation | 95.65% transfer efficiency for CEGs | Demonstrates potential for horizontal gene transfer in hospital settings | paper
• assay | ERIC-PCR genotyping | 17 genotypes identified | Resolves clonal diversity and tracks outbreak lineages | paper
• assay | Use of bacterial protein synthesis inhibitors (e.g., Amikacin) | Typically 5–100 μg/mL in broth | Applicable for resistance and inhibition profiling in CREC and Klebsiella pneumoniae | workflow_recommendation

Comparison with Existing Internal Articles

Several recent internal resources elaborate on the molecular utility of Amikacin (BAY416651) in multidrug resistance research. For example, "Amikacin (BAY416651): Applied Workflows for Resistance Research" emphasizes the compound's robustness as a bacterial protein synthesis inhibitor—especially in the context of Enterobacter cloacae and Klebsiella pneumoniae resistance mechanisms (internal_article). Similarly, "Amikacin (BAY416651): Molecular Insights and Resistance Dynamics" bridges the effectiveness of amikacin with the genetic backdrop of aminoglycoside acetyltransferase AAC (6')-I resistance, which is pertinent given the rising prevalence of such enzymes in carbapenemase-producing strains (internal_article). These resources supplement the current study by offering actionable experimental protocols and troubleshooting advice for resistance gene tracking and phenotypic assays.

Limitations and Transferability

The primary limitation of the reference study lies in its regional scope: all isolates were collected from a single province, potentially limiting generalizability to other geographic or healthcare contexts. The study also focuses on a discrete set of CEGs, leaving out less common carbapenemase variants. While the high transferability of CEGs is demonstrated in vitro, the dynamics in vivo, including environmental and host-related factors influencing gene spread, require further investigation. Nevertheless, the rigorous integration of molecular, epidemiological, and phenotypic data provides a robust foundation for extrapolating risk factors and intervention points in similar healthcare environments (paper).

Research Support Resources

Researchers investigating antibiotic resistance mechanisms, especially in multidrug-resistant Enterobacteriaceae, can benefit from using bacterial protein synthesis inhibitors such as Amikacin (BAY416651) Aminoglycoside Antibiotic (SKU B3431). Amikacin is notable for its stability against most aminoglycoside-modifying enzymes, making it suitable for resistance profiling in CREC and Klebsiella pneumoniae workflows (internal_article). For detailed experimental strategies and troubleshooting, consult dedicated resistance research workflow guides available through APExBIO and affiliated platforms.